Onset: Approx 15 minutes 3-5 minutes (IV) 10-20 minutes (oral).ĭuration: Up to 6 hours (IM) 90% (IM). Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to Cl ions, which results in hyperpolarisation and stabilisation. respiratory depression, respiratory arrest, apnoea, cardiac arrest).ĭescription: Midazolam binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at various sites within the CNS, including limbic system and reticular formation. Potentially Fatal: Cardiorespiratory effects (e.g. Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus. Respiratory, thoracic and mediastinal disorders: Dyspnoea, laryngospasm, bronchospasm, cough. Psychiatric disorders: Confusion, euphoric mood, depression, hallucinations, physical drug dependence, withdrawal syndrome. Nervous system disorders: Sedation (prolonged and post-operative), decreased alertness, somnolence, headache, dizziness, drowsiness, ataxia. Musculoskeletal and connective tissue disorders: Muscle weakness. Injury, poisoning and procedural complications: Falls, fractures. General disorders and administration site conditions: Fatigue, inj site reactions (e.g. Gastrointestinal disorders: Nausea, vomiting, constipation, dry mouth, hiccups. hyperactive or aggressive behaviour), suicidal ideation, withdrawal symptoms.Ĭardiac disorders: Bradycardia, tachycardia. Significant: Anterograde amnesia, CNS depression, hypotension, paradoxical reactions (e.g.
0 kommentar(er)
